Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ICER Boosts ‘Cost-Recovery’ Benchmark Price For Remdesivir To Reflect Gilead’s Planned R&D

Executive Summary

But updated pricing model also suggests the more traditional cost effectiveness’ benchmark price for remdesivir could be lower than previously estimated to account for use of dexamethasone in reducing the underlying risk of mortality in COVID-19 patients.

You may also be interested in...

Paxlovid, Molnupiravir, Sotrovimab Appear Cost Effective To ICER; But Data, Price Could Change

With the US government currently negotiating prices and drugs mostly going to high-risk patients, ICER’s draft ‘special assessment’ of COVID treatments offers an approach to adapting research on safety and effectiveness in order to provide guidance to clinicians, payers and other stakeholders.

Coronavirus Update: Spooked By America’s COVID-19 Vaccine Skepticism, FDA Promises Not To Lower Standards

The FDA has released detailed guidance to COVID-19 vaccine manufacturers setting out the safety and efficacy standards required, and pledged to not cut corners.

Gilead’s Remdesivir Pricing Sets ‘Promising’ Precedent For Future COVID-19 Drugs

Highly anticipated decision bodes well for pricing of other future treatments for the disease, the US Institute for Clinical and Economic Review suggests.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts